<DOC>
	<DOCNO>NCT00077857</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety label dose capecitabine ( Xeloda® ) low dose Xeloda® plus docetaxel ( Taxotere® ) patient locally advance metastatic breast cancer failure chemotherapy anthracycline . Patients randomize receive either 1250 mg/m^2 825 mg/m^2 orally twice day ( po bid ) day 1-14 3 week cycle , combination Taxotere® 75 mg/m2 intravenous ( iv ) day 1 3 week cycle . The anticipated time study treatment disease progression target sample size 440 individual .</brief_summary>
	<brief_title>A Study Assess Capecitabine ( Xeloda® ) Patients With Locally Advanced Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>woman &gt; =18 year age ; &gt; =1 target lesion ; locally advance metastatic breast cancer ; demonstrate resistance anthracycline ; &gt; =2 regimen chemotherapy advanced/metastatic disease . previous treatment Xeloda , continuous 5fluorouracil infusion , oral fluoropyrimidines ; previous treatment paclitaxel docetaxel advanced/metastatic disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
</DOC>